Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.
Shook BC, Rassnick S, Chakravarty D, Wallace N, Ault M, Crooke J, Barbay JK, Wang A, Leonard K, Powell MT, Alford V, Hall D, Rupert KC, Heintzelman GR, Hansen K, Bullington JL, Scannevin RH, Carroll K, Lampron L, Westover L, Russell R, Branum S, Wells K, Damon S, Youells S, Beauchamp D, Li X, Rhodes K, Jackson PF. Shook BC, et al. Among authors: bullington jl. Bioorg Med Chem Lett. 2010 May 1;20(9):2868-71. doi: 10.1016/j.bmcl.2010.03.024. Epub 2010 Mar 7. Bioorg Med Chem Lett. 2010. PMID: 20338760
Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.
Shook BC, Rassnick S, Hall D, Rupert KC, Heintzelman GR, Hansen K, Chakravarty D, Bullington JL, Scannevin RH, Magliaro B, Westover L, Carroll K, Lampron L, Russell R, Branum S, Wells K, Damon S, Youells S, Li X, Osbourne M, Demarest K, Tang Y, Rhodes K, Jackson PF. Shook BC, et al. Among authors: bullington jl. Bioorg Med Chem Lett. 2010 May 1;20(9):2864-7. doi: 10.1016/j.bmcl.2010.03.042. Epub 2010 Mar 11. Bioorg Med Chem Lett. 2010. PMID: 20347304
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
Shook BC, Rassnick S, Osborne MC, Davis S, Westover L, Boulet J, Hall D, Rupert KC, Heintzelman GR, Hansen K, Chakravarty D, Bullington JL, Russell R, Branum S, Wells KM, Damon S, Youells S, Li X, Beauchamp DA, Palmer D, Reyes M, Demarest K, Tang Y, Rhodes K, Jackson PF. Shook BC, et al. Among authors: bullington jl. J Med Chem. 2010 Nov 25;53(22):8104-15. doi: 10.1021/jm100971t. Epub 2010 Oct 25. J Med Chem. 2010. PMID: 20973483
Inhibitors of unactivated p38 MAP kinase.
Bullington J, Argentieri D, Averill K, Carter D, Cavender D, Fahmy B, Fan X, Hall D, Heintzelman G, Jackson P, Leung WP, Li X, Ling P, Olini G, Razler T, Reuman M, Rupert K, Russell R, Siekierka J, Wadsworth S, Wolff R, Xiang B, Zhang YM. Bullington J, et al. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6102-6. doi: 10.1016/j.bmcl.2006.08.101. Epub 2006 Sep 12. Bioorg Med Chem Lett. 2006. PMID: 16971122
Pyridinylimidazole based p38 MAP kinase inhibitors.
Jackson PF, Bullington JL. Jackson PF, et al. Among authors: bullington jl. Curr Top Med Chem. 2002 Sep;2(9):1011-20. doi: 10.2174/1568026023393372. Curr Top Med Chem. 2002. PMID: 12171568 Review.
The development of novel and selective p56lck tyrosine kinase inhibitors.
Bullington JL, Cameron JC, Davis JE, Dodd JH, Harris CA, Henry JR, Pellegrino-Gensey JL, Rupert KC, Siekierka JJ. Bullington JL, et al. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2489-94. doi: 10.1016/s0960-894x(98)00445-4. Bioorg Med Chem Lett. 1998. PMID: 9873567